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Purpose: To explore the association between the degree of Chronic illness management and sur-
vival rates at 1-, 3-, 5-years post heart transplantation.
Methods: Exploratory secondary analysis of a cross-sectional, international study (Building
Research Initiative Group study). Latent profile analysis was performed to classify 36 heart trans-
plant centers according to the degree of chronic illness management.
Results: The analysis resulted in 2 classes with 29 centers classified as “low-degree chronic illness
management” and 7 centers as “high-degree chronic illness management”. After 1-year posttrans-
plantation, the high-degree chronic illness management class had a significantly greater mean
survival rate compared to the low-degree chronic illness management class (88.4% vs 84.2%,
p= 0.045) and the difference had a medium effect size (η2= .06). No difference in survival for
the other time points was observed. Patients in high-degree chronic illness management centers
had 52% lower odds of moderate to severe drinking (95% confidence interval .30–.78, p= 0.003).
No significant associations between degree of chronic illness management and the other recom-
mended health behaviors were observed.
Conclusions: The findings from this exploratory study offer preliminary insight into a system-
level pathway (chronic illness management) for improving outcomes for heart transplant recipi-
ents. The signals observed in our data support further investigation into the effectiveness of
chronic illness management-based interventions in heart transplant follow-up care.
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Introduction
Despite the significant improvement in physical
function and quality of life posttransplantation,1
heart transplant (HTx) recipients are still consid-
ered to have a chronic condition since they have
to adhere to a life-long complex therapeutic
regimen and regular medical follow-up to
monitor graft function and prevent or treat
co-morbidities.2 Given the multifaceted nature
of the post-transplant regimen and the impact
of behavioral and psychosocial factors on HTx
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outcomes,1,3 HTx recipients would greatly
benefit from a comprehensive follow-up care
that not only addresses biomedical parameters
but psychosocial and behavioral functioning
as well.4,5
Chronic illness management (CIM) is an
innovative approach to transplant follow-up
care that could improve the health outcomes of
HTx recipients.4 Unlike the prevailing acute
care model, wherein the patient initiates the
search for care in response to an acute exacerba-
tion of a current condition or the emergence of a
new condition,6 CIM takes a more proactive
approach by ensuring continuity of care, prevent-
ive measures, and providing the patient with
adequate self-management support throughout
his/her long-term illness trajectory.6 The
Innovative Care for Chronic Conditions (ICCC)
framework provides a roadmap for health
system re-engineering to make it more conducive
to the needs of patients with chronic conditions.7
Under the ICCC framework, healthcare systems
are encouraged to (1) promote continuity of
care and care coordination; (2) improve quality
through leadership and incentives; (3) organize
and equip healthcare teams; (4) utilize informa-
tion systems; and (5) support disease self-
management and prevention.6 Changes in this
direction would make healthcare systems better
equipped to care for individuals with chronic con-
ditions, who require long-term integrated care
and support, such as HTx recipients.
Integrated care—defined as health services
delivered throughout the health continuum and
coordinated across different levels and sites of
care8—when based on principles of CIM has
resulted in improved outcomes in other chronic-
ally ill populations. Among people with multiple
chronic conditions, comprehensive care based
on CIM principles has been shown to improve
health behaviors, decrease healthcare utilization
and healthcare costs.9 In HTx, variability in
degrees of CIM among centers has been
observed,10 yet the association between CIM
and clinical outcomes have not yet been explored.
Therefore, the primary aim is to explore the
association between the degree of CIM and
survival rates at 1-, 3-, 5-years post HTx at
the center-level. Additionally, the associations
between the degree of CIM and more proximal
outcomes (i.e. patients’ adherence to recom-
mended health behaviors) will be explored.
Methods
This is a secondary analysis of the Building
Research Initiative Group: CIM and Adherence
in Transplantation (BRIGHT) study, a cross-
sectional study that examined the multi-level
factors associated with immunosuppressant non-
adherence in adult HTx recipients from 36 HTx
centers in 11 countries across 4 continents.11
Information on the methodology of the
BRIGHT study has been previously pub-
lished.11–13 Data were collected between March
2012 and October 2015.
Sampling strategy
The BRIGHT study used a multi-staged sam-
pling approach. A convenience sample of
countries and HTx centers were recruited, fol-
lowed by a random sample of clinicians and
patients using a sampling strategy guided by
the size of the HTx centers. Centers that per-
formed 50-74 HTx in 5 years were classified
as small, centers performing 75–100 HTx as a
medium, and those performing >100 HTx as
large.12 The size classification of the HTx
centers was determined using the variability
in the number of HTx performed by the partici-
pating centers and the International Society of
Heart and Lung Transplantation (ISHLT) cri-
teria.14 Twenty-five patients were randomly
recruited from small HTx centers, 40 from
medium centers, and 60 from large centers. If
the center had ≤5 eligible clinicians, all were
recruited. In centers with >5 eligible clinicians,
a random sample of 5 clinicians was recruited.
Inclusion criteria
Countries. To be included, a country needed to
have at least two eligible HTx centers.
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HTx Centers. A center was eligible to par-
ticipate if ≥50 HTx had been performed during
the 1–5 years prior to study enrollment.
Clinicians. To be eligible, clinicians had to
meet the following criteria: (1) working in the
center for >6 months; (2) being employed in
direct clinical practice ≥50%; and (3) being
familiar with the post-transplant outpatient
care at the center (e.g. physicians, nurses, trans-
plant coordinators).
HTx Patients. HTx recipients had to meet
the following criteria in order to be eligible:
(1)≥18 years of age at the time of inclusion;
(2) first transplant; (3) single-organ transplant;
(4) transplanted and followed up for routine
care in a participating HTx center; (5)
between 1 and 5 years post-transplant; and
(6) able to read, understand, and sign an
informed consent in the language of the partici-
pating HTx center. Patients were excluded if
they were currently receiving professional
support in taking their medications or if they
participated in a clinical trial during the past 6
months.
Variables and measures
Degree of CIM. The degree of CIM was
assessed from two perspectives (patients’ and
clinicians’) to obtain a more accurate picture
of the CIM practices of each HTx center. The
validated short version of the Patient
Assessment of Chronic Illness Care (PACIC)
was used to measure the extent to which the
CIM provided is congruent with the chronic
care model from the patient’s perspective
(Cronbach’s alpha= 0.955; test-retest reliabil-
ity (r)= 0.638).15,16 The short self-report
version consists of 11 items and uses a
5-point Likert scale from “almost never” to
“almost always”. The summary score ranges
from 11 to 55 with higher scores indicating a
higher degree of CIM. For this study, the
patients’ PACIC scores were averaged per
center, generating a CIM score per center as
perceived by patients being followed up
within a given center.
The Chronic Illness Management
Implementation-Building Research Initiative
Group: CIM and Adherence in
Transplantation (CIMI-BRIGHT) instrument
was used to assess CIM implemented in the
HTx centers from the clinicians’ perspec-
tives.17 The CIMI-BRIGHT consists of 52
items and uses a 4-point Likert scale from
“strongly disagree= 1” to “strongly agree=
4”.17 The CIMI-BRIGHT allows for a “don’t
know” response (coded as “5”); therefore, the
“don’t know” responses were treated as
missing and the CIMI-BRIGHT scores were
averaged per clinician. The clinicians’
CIMI-BRIGHT scores were then averaged
per center with higher scores corresponding
to a higher degree of CIM implemented.
Behavioral factors. Behavioral factors were ana-
lyzed at the patient level. Immunosuppressant
adherence was assessed using the Basel
Assessment of Adherence to Immunosuppressive
Medications Scale (BAASIS).18,19 Any deviation
in taking, dosing, or timing was considered
nonadherence.18 Adherence to other medica-
tions, including the different implementation
dimensions (i.e. dosing, timing),20,21 was
assessed using an adapted version of the
BAASIS. The level of physical activity was
measured using the Brief Physical Activity
Assessment Tool.22 Patients were deemed
adherent if they engaged in 20 min of vigorous
physical activity ≥3 times/week or 30 min of
moderate physical activity ≥5 times/week or
5 or more sessions of any combination of mod-
erate and vigorous-intensity physical activity.22
Dietary adherence was measured by asking
the patients if they were advised to follow a
specific diet in the past year and, if so, how
strictly they followed the recommended diet
(never/rarely/sometimes/ often/ always). The
subsample of patients, who were recom-
mended a specific diet, were then classified
as adherent if they followed their recommended
diets often/always. Patients who were current
smokers were classified as non-adherent, and
patients who never smoked or quit were
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considered adherent. Patients who were non-
drinkers or mild drinkers (i.e. <1 drink/day for
females and <2 drinks/day for males) were clas-
sified as adherent and were classified as non-
adherent if they were moderate or heavy drinkers.
Finally, patients who used sun protection (wear a
hat, use sunscreen, stay in the shadows, or limit
sun exposure often or all the time) were classified
as adherent and those who did not as non-
adherent. A detailed description of the measures
used is published elsewhere.11
Survival rates. An investigator-developed, self-
report questionnaire completed by the center’s
director asked for center-level survival data
and mortality risk factors that pertained to all
patients at the center and not exclusively for
those participating in BRIGHT. Survival rates
were requested at 1, 3, and 5 years post-
transplantation, congruent with the inclusion cri-
terion (i.e. patient included were 1 till 5 years
post-transplant). We assessed specific risk
factors of HTx mortality: i.e. the percentage of
patients: hospitalized at the time of HTx, with
infection requiring IV drug therapy, with defib-
rillator prior to HTx, on ventilator at time of
HTx, on extracorporeal membrane oxygenation
(ECMO) at time of HTx, with intra-aortic
balloon pump at time of HTx, or on ventricular
assist device (VAD) at HTx, etiology of heart
failure, and recipient gender/donor gender.
Ethical considerations
Each BRIGHT study HTx center obtained
ethical approval from their institutional
review board and/or national ethics committee.
Written informed consent was obtained from
the participating HTx recipients. Finally, com-
pleted questionnaires were coded by the HTx
center and returned to the investigators in
sealed envelopes to maintain confidentiality.
Statistical analyses
For this secondary analysis, data were analyzed
at the center-level (i.e. PACIC and
CIMI-BRIGHT scores were averaged by HTx
center), except in the analysis of the associa-
tions between degree of CIM and recom-
mended health behaviors that used
patient-level data (n= 1397 patients).
Analysis was performed using Stata/SE 15.
Based on the current state of science, we used
the most appropriate and innovative method to
classify the HTx centers. Latent profile analysis
(LPA) is a measurement model in which indivi-
duals, or in this case centers, are classified into
mutually exclusive and exhaustive groups
based on how they perform on a set of continu-
ous indicator variables. The 2-step LPA proced-
ure suggested by K.E. Masyn23,24 was
performed to classify the HTx centers into
groups based on their degree of CIM (mean
PACIC and CIMI-BRIGHT scores). The
2-step approach comprised of (1) identifying
latent groups using observed indicator variables
(PACIC and CIMI-BRIGHT scores); and (2)
assigning centers to groups based on predicted
posterior class probabilities.23 Models with two
to four groups were estimated and compared
based on goodness-of-fit indices and interpret-
ability. The goodness-of-fit indices evaluated
comprised of the Bayesian information criterion
(BIC) and Akaike information criterion (AIC),
wherein lower values correspond to better
model fit.23
Sensitivity analysis was performed by using
the median PACIC and CIMI-BRIGHT scores
as the cutoff to classify the centers into two
groups (high-/low-degree of CIM), which
resulted in similar findings.
Fisher’s exact test was used to compare the
center characteristics and HTx mortality risk
factors between the two groups identified by
the LPA. Meanwhile, logistic regression was
used to compare the patients’ adherence to
recommended health behaviors between the
two CIM groups. Lastly, the mean survival
rates at 1-, 3-, and 5 years between the two
groups were compared using a random-
intercepts regression analysis and partial
eta-squared (η2) were calculated to determine
effect sizes.
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Results
Characteristics of the 36 HTx centers and their
respective mean degrees of CIM are presented
in Table 1. Over half (n= 19, 52.8%) of the
centers were located in Europe, 12 (33.3%)
were located in North America, 3 (8.3%) in
South America, and 2 (5.6%) in Australia.
Twenty-three (63.9%) were large centers (i.e.
>100 HTx performed/5 years). Thirty-two
(88.9%) of the HTx centers were located in
urban areas and the majority (83.3%) were uni-
versity teaching hospitals. The degree of CIM
varied across countries. The overall mean
PACIC score was 37.9± 4.7 (range: 30.9–
42.0) and the overall mean CIMI-BRIGHT
score was 2.9± .3 (range: 2.7–3.1).
Based on the 2-step LPA, the 2-group
model had the best fit (lowest BIC and AIC
values). Using the 2-group model, 29 HTx
centers were classified under groups 1 and 7
in group 2. After checking the mean degree
of CIM for each group, group 1 was labeled
as “low-degree CIM” and group 2 as “high-
degree CIM”. The mean PACIC score for
group 1 was 36.9± 4.1 and 42.0± 4.8 for
group 2. The mean CIMI-BRIGHT score
for group 1 was 2.8± .2 and 3.3± .2 for
group 2. There were no significant differences
between the groups in terms of center charac-
teristics (i.e. size, location, type), center-level
mortality risk factors, etiology of heart
failure, and recipient gender/donor gender,
except for the percentage of patients with idio-
pathic (p= 0.034), congenital (p= 0.013), and
other etiology of heart failure (p= 0.026). A
comparison of the center-level characteristics
between the two groups is presented in Table 2.
Figure 1 shows the comparison of the sur-
vival rates between the low-degree CIM
group and the high-degree CIM group.
Information on survival rates for adult HTx
performed between 2010 and 2017 from the
ISHLT registry is also included for reference.25
Not every HTx center provided information on
their survival rate. At year 1, only 31 centers
had available information on their survival
rates. At years 3 and 5, only 29 and 30 HTx
centers, respectively, had available survival
rates. It should be noted that all 7 high-degree
CIM centers provided information on their sur-
vival rates for years 1, 3, and 5; hence, the
missing survival rates were all from low-degree
CIM centers. At year 1, being in a high-degree
CIM center was associated with a 4.8% higher
survival rate (95% confidence interval (CI)
.11–9.4, p= 0.045) and the difference had a
medium effect size (η2= .06). There were no
significant differences in survival rates at
years 3 (η2= .01) and 5 (η2 < .0001).
Patients in high-degree CIM centers had 9%
higher odds of adhering to their immunosup-
pressants (95% CI .83 -1.43, p= 0.54) and 8%
higher odds of adhering to their other medica-
tions (95% CI .76–1.55, p= 0.66) compared to
patients in low-degree CIM centers. Similarly,
patients in high-degree CIM centers had 33%
higher odds of engaging in sufficient physical
activity (95% CI .94–1.90, p= 0.11), 34%
lower odds of smoking (95%CI .29–1.49, p=
0.32), and 52% significantly lower odds of mod-
erate to severe drinking (95%CI .30–.78, p=
0.003). Conversely, patients in high-degree
CIM centers had 21% lower odds of using sun
protection (95%CI .54–1.13, p= 0.20). Lastly,
patients in high-degree CIM centers had 49%
significantly higher odds of being recommended
a specific diet (95%CI 1.13–1.96, p= 0.004).
However, in the subsample of 450 patients
who received diet recommendations, patients
from high-degree CIM centers had 21% lower
odds of adhering to diet recommendations
(95%CI .51–1.22, p= 0.29).
Discussion
The findings from this exploratory study offer
preliminary insight into the potential of CIM,
as a system-level pathway, in improving short-
term survival for HTx recipients. HTx centers
with higher degrees of CIM had a better sur-
vival rate in year 1 compared to centers with
lower degrees of CIM. However, our findings
do not support an association between degree
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of CIM and longer-term survival at 3- and
5-years post transplant. The cross-sectional
design of the BRIGHT study meant that
the degree of CIM was measured at only one
time-point, making it difficult to ascertain the
HTx centers’ degrees of CIM at the different
time points. It is possible that the centers with
high-degree CIM had only recently implemented
CIM practices, which could help explain the lack
of associations in the later timepoints.








PACIC 36.9± 4.1 42.0± 4.8 0.024a
CIMI-BRIGHT 2.8± .2 3.3± .2 <0.001a
Size 0.896b
Large 19 (65.5%) 4 (57.1%)
Medium 6 (20.7%) 2 (28.6%)
Small 4 (13.8%) 1 (14.3%)
Location 0.581b
Urban 25 (86.2%) 7 (100%)
Suburban 3 (10.3%) –
Rural 1 (3.5%) –
Center type 0.492b
University 25 (86.2%) 5 (71.4%)
Community 3 (10.3%) 1 (14.3%)
Other 1 (3.5%) 1 (14.3%)
Mortality risk factorsc
% hospitalized at time of Tx 50% 30% 0.072a
% with infection 12% 20% 0.394a
% with defibrillator 57% 53% 0.650a
% on ventilator 5% 3% 0.804a
% on ECMO 7% 3% 0.705a
% with balloon pump 12% 8% 0.804a
% with VAD 17% 13% 0.742a
Etiology of heart failure
% Ischemic 31% 32% 0.646a
% Dilated Cardiomyopathy 53% 40% 0.034a
% Valvular 3% 2% 0.902a
% Congenital 5% 0.3% 0.013a
% Other 8% 26% 0.026a
Recipient Gender/donor gender
% Female/female 20% 17% 0.430a
% Female/male 11% 16% 0.249a
% Male/male 53% 52% 0.808a
% Male/female 16% 15% 0.808a
aMann–Whitney U test.
bFisher’s exact test.
c% of patients (n1= number of low-level centers; n2= number of high-level centers).
PACIC: patient assessment of chronic illness care; CIMI-BRIGHT: chronic illness management implementation-building
research initiative group; CIM: chronic illness management; ECMO: extracorporeal membrane oxygenation; VAD:
ventricular assist device.
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Similarly, when looking into more proximal
outcomes—specifically adherence to recom-
mended health behaviors—despite the trend
toward better adherence there was a lack of
statistically significant associations. Given
that CIM is a system-level factor, its associ-
ation with health behaviors could be indirect
in nature through more person-level factors,
such as self-efficacy and/or patient activation,
which are widely known to impact behavior
change.26,27 At an intuitive level, it is logical
to expect that the proactive, holistic support
provided by a multidisciplinary team of health-
care professionals—the crux of CIM—would
increase the patient’s confidence, knowledge,
and skills in performing recommended health
behaviors. Unfortunately, given the secondary
nature of this analysis, the associations
between CIM and person-level behavioral
factors could not be explored.
Previous studies on renal transplant
recipients provide proof of concept that
re-engineering transplant follow-up care using
CIM principles could be a promising solution
to improving long-term transplant outcomes.
Bissonnette and colleagues showed that trans-
plant follow-up care based on CIM principles
was effective in helping transplant recipients
achieve targeted clinical outcomes.28
Meanwhile, in a randomized-controlled trial,
Schmid et al. showed that a telemedically sup-
ported CIM intervention resulted in better
adherence to immunosuppressants, fewer hos-
pitalizations, and shorter lengths of hospital
stay.29
Admittedly, designing a CIM intervention
will require adapted methods beyond the trad-
itional clinical research methods to achieve
successful implementation, adoption, and sus-
tainability of an innovative model of care
for follow-up of transplant patients.30
Implementation science could offer a way
forward to achieve success in this regard.31
We are currently investing in developing,
implementing, and testing this CIM-based
eHealth-powered integrated care model—
consisting of a human-component (i.e. care
coordinator) as well as technology factors
(i.e. SMILE app)—using the principles of user-
centered design, agile software development,
as well as implementation science to improve
outcomes in stem cell transplant patients.32
This model, should it prove to be successfully
implemented in variable contexts and should
it prove to be effective in improving clinical
outcomes as well, could provide a blue print
for solid organ transplantation to reengineer
follow-up care based on principles of CIM.
Findings from the present exploratory
study should be interpreted within the
Figure 1. Mean HTx patient survival by level of chronic illness management.
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context of its limitations. First, the cross-
sectional design precludes causal inferences.
Second, this secondary analysis had a small
sample size (center-level), which means it
could have been underpowered to detect dif-
ferences in survival rates. Similarly, we
could not rule out the potential impact of sur-
vival bias. Moreover, the small sample size
(center-level) prevented us from controlling
for potential confounders in our analyses as
mentioned before. Nonetheless, potential con-
founders were analyzed descriptively to
provide context to our findings. Lastly, the
primary outcome (survival rates) was mea-
sured using self-report which could limit the
validity of our findings. On the other hand, a
strength of this study is the assessment of
CIM from two independent perspectives
(patients and clinicians), and the use of these
two measures in the analysis.
Conclusion
Significant association between degree of CIM
and short-term survival hints at the potential
impact of CIM. The signals observed in our
data—combined with the emerging evidence
from intervention studies supporting the effect-
iveness of the CIM approach in renal transplant
follow-up care—compels further investigation.
Our findings help justify the development and
testing of CIM-based interventions for HTx
recipients. In addition, future research should
explore what degree of CIM and which
aspects of CIM are most relevant in view of
achieving better outcomes in transplantation.
Degree of CIM needs to be regarded as a valu-
able system-level factor that expresses the
extent to which Tx centers have adopted princi-
ples of chronic illness care.
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